The Liver Meeting 2022-Hepatitis B SIG Program: Navigating HBV treatment and cure by starting or stopping nucleos(t)ide analogues (NUC)

Hepatitis B SIG Program: Navigating HBV treatment and cure by starting or stopping nucleos(t)ide analogues (NUC)

Video Transcription

Video Summary

In this video, the speakers discuss the treatment and cure options for Hepatitis B. They discuss the benefits of long-term nucleoside analog therapy in suppressing the virus and controlling the disease, but they also acknowledge the limitations of current treatments in achieving a cure. The speakers highlight the need to expand treatment criteria and discuss specific patient populations that may require special consideration in their treatment approach. They provide insights into different nucleoside analogs and how they may be used in different patient populations. The video also explores the potential efficacy and risks of stopping nucleoside analog therapy, including the possibility of achieving hepatitis B surface antigen loss but also the risk of viral flares. Overall, the video emphasizes the need for further research and individualized treatment approaches in order to improve outcomes for patients with Hepatitis B. Additionally, the video features a panel discussion on the treatment and monitoring of patients with chronic Hepatitis B. There is debate over the adoption of a "treat all" approach, similar to HIV management, and concerns about feasibility and patient adherence. The panel discusses nucleoside analog withdrawal in certain patient populations and highlights the potential benefits and risks. They also touch on new treatment agents and the management and monitoring of patients who experience flares. The panel emphasizes the importance of personalized treatment based on viral and host factors and the need for standardized stopping and monitoring criteria for nucleoside analog withdrawal.

Asset Caption

During this session the HBV SIG will address what the treatment indications are for HBV, and how to treat chronic HBV patients with NUC in the best way. During the second part of the session, we will address the pros and cons of NUC withdrawal

Keywords

Hepatitis B

treatment options

cure options

nucleoside analog therapy

virus suppression

disease control

treatment limitations

expanding treatment criteria

specific patient populations

viral flares

research

panel discussion

personalized treatment